CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …

Abstract Cytochrome P450 (CYP) family 1, 2, and 3 enzymes play an essential role in the
metabolic clearance and detoxification of a myriad of structurally and chemically diverse …

Charge-transfer interactions (CT) between the electron donor gliclazide (GLC) and the π-
acceptors 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ) and tetracyanoethylene …

Gut microbiota and bile acids possess the ability to modify absorption and pharmacokinetic
profile of numerous drugs. Since the variability of gliclazide response in patients cannot be …

Synthetic cannabinoids (SCBs), synonymous with 'K2','Spice'or 'synthetic marijuana', are
psychoactive drugs of abuse that frequently result in clinical effects and toxicity more severe …

Abstract CYP2C9 metabolizes approximately 20% of clinically used drugs, including the
narrow therapeutic window drugs warfarin and phenytoin. More than 16,000 variants have …

Cytochrome P450s (CYP) represent a superfamily of b-type hemoproteins catalyzing
oxifunctionalization of a vast array of endogenous and exogenous compounds. The present …

Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of
noninsulin-dependent diabetes mellitus. It belongs to the sulfonylurea class that stimulates …

Charge transfer interactions (CT) between a gliclazide (GLC) donor and a picric acid (PA) π
acceptor or iodine σ acceptor, were studied in a chloroform solution and in the solid state …

Single nucleotide polymorphisms detected in the solute carrier member family-22 has been
shown to result in a variable response in the treatment of type 2 diabetes mellitus with …